Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

All news Pharmasist News & insight

Pendopharm recalls seven lots of diphenhydramine capsules across Canada

Health Canada lists four lots of PDP-diphenhydramine 25 mg and three of 50 mg in a national retailer-level recall over an impurity that may exceed specifications.

1 min read2 sources
Share LinkedIn X Facebook Email
Illustrative photo accompanying this news article
Illustrative photograph of capsules spilling from a bottle. Photo by NIAID via Wikimedia Commons (CC BY 2.0). Image source Image source
In this article & details

Article details

Published
Nov 10, 2026
Reading time
1 min read
Categories
Medication Safety, Recalls
Jurisdiction
National
Sources cited
2
All news

Pendopharm is recalling seven lots of PDP-diphenhydramine capsules distributed across Canada after identifying an impurity that may exceed the product’s specifications. Health Canada posted the recall Nov. 9 and said it reaches retailers. It includes four lots of the 25 mg capsule and three lots of the 50 mg capsule. Health Canada recall notice

Which diphenhydramine lots are affected?

25 mg · DIN 00757683
Lots 638997, 658003, 664380, 669604
50 mg · DIN 00757691
Lots 653809, 658757, 664907

Health Canada identified the impurity as N-nitroso-N-desmethyl diphenhydramine and classified the action as a Type II recall. The agency linked an earlier Oct. 5 notice about the same impurity in a separate set of 25 mg lots. The November notice lists affected lots for both strengths. November lot list · October recall notice

Health Canada advises patients to check whether their lot is affected and speak to a healthcare provider before stopping an affected product or if they have health concerns. It directs questions about the recall to Pendopharm, a division of Pharmascience, and accepts reports of suspected side effects. Recall contacts and reporting instructions

References

  1. PDP-diphenhydramine 25 mg and 50 mg capsules recall — Health Canada, RA-82928, Nov. 9, 2026
  2. Earlier PDP-diphenhydramine 25 mg capsule recall — Health Canada, RA-82720, Oct. 5, 2026

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.